Hypofractionated Stereotactic Body Radiation Therapy for Patients With Prostate Cancer That Was Removed by Surgery
Phase I Dose-Escalation Study of Hypofractionated SBRT for Adjuvant/Salvage Radiotherapy in Prostate Cancer
Sponsor: National Cancer Institute (NCI)
A NA clinical study on Stage II Prostate Adenocarcinoma and Stage IIB Prostate Cancer, this trial is ongoing. The trial is conducted by National Cancer Institute (NCI) and has accumulated 14 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Jan 2025 — Present [monthly]
Unknown NA
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Jan 2025 [monthly]
Active Not Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting NA
-
Jan 2023 — Jul 2024 [monthly]
Active Not Recruiting NA
-
Sep 2022 — Jan 2023 [monthly]
Active Not Recruiting NA
▶ Show 9 earlier versions
-
Dec 2021 — Sep 2022 [monthly]
Active Not Recruiting NA
Status: Unknown Status → Active Not Recruiting
-
Oct 2021 — Dec 2021 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting NA
-
Feb 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
-
Jun 2019 — Feb 2020 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Jun 2019 [monthly]
Recruiting NA
-
May 2017 — Jun 2018 [monthly]
Recruiting NA
Phase: PHASE1 → NA
-
Feb 2017 — May 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
May 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- University of Southern California
For direct contact, visit the study record on ClinicalTrials.gov .